Tonix Pharmaceuticals Holding Corp. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
Dec. 31, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 17 – SUBSEQUENT EVENTS On January 11, 2021, the Company entered into a securities purchase agreement with certain institutional investors relating to the issuance and sale of 50,000,000 shares of its common stock in a registered direct public offering (“the January 2021 Financing”), with AGP as placement agent. The public offering price for each share of common stock was $0.80. The January 2021 Financing closed on January 13, 2021. AGP received a cash fee of 7% of the gross proceeds, for an aggregate of $2.8 million. The Company incurred other offering expenses of approximately $0.3 million. The Company received net proceeds of approximately $36.9 million, after deducting the fees and other offering expenses. On February 8, 2021, the Company entered into agreement securities purchase agreement with certain institutional investors relating to the issuance and sale of 58,333,334 shares of its common stock in a registered direct public offering(“the February 2021 Financing”), with AGP acting as placement agent. The public offering price for each share of common stock was $1.20. The February 2021 Financing closed on February 9, 2021. AGP received a cash fee of 7% of the gross proceeds, for an aggregate of $4.9 million. The Company incurred other offering expenses of approximately $0.1 million. The Company received net proceeds of approximately $65.0 million, after deducting the fees and other offering expenses. On February 23, 2021, the Company granted options to purchase an aggregate of 7,655,875 shares of the Company’s common stock to employees with an exercise price of $1.22, with a term of ten years, vesting 1/3 on the first anniversary and 1/36th each month thereafter for 24 months. Additionally, the Company granted options to purchase 4,830,000 shares of the Company’s common stock to certain employees with an exercise price of $1.53, with a term of ten years, vesting 1/3 on the first anniversary and 1/36th each month thereafter for 24 months. On March 5, 2021, the Company announced that it entered into a $2.9 million non-binding Purchase and Sales Agreement in connection with a property in Massachusetts. The Property is intended for process development activities.

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2020

NOTE 17 – SUBSEQUENT EVENTS

On January 11, 2021, the Company entered into a securities purchase agreement with certain institutional investors relating to the issuance and sale of 50,000,000 shares of its common stock in a registered direct public offering (“the January 2021 Financing”), with AGP as placement agent. The public offering price for each share of common stock was $0.80. The January 2021 Financing closed on January 13, 2021. AGP received a cash fee of 7% of the gross proceeds, for an aggregate of $2.8 million. The Company incurred other offering expenses of approximately $0.3 million. The Company received net proceeds of approximately $36.9 million, after deducting the fees and other offering expenses.

On February 8, 2021, the Company entered into agreement securities purchase agreement with certain institutional investors relating to the issuance and sale of 58,333,334 shares of its common stock in a registered direct public offering(“the February 2021 Financing”), with AGP acting as placement agent. The public offering price for each share of common stock was $1.20. The February 2021 Financing closed on February 9, 2021. AGP received a cash fee of 7% of the gross proceeds, for an aggregate of $4.9 million. The Company incurred other offering expenses of approximately $0.1 million. The Company received net proceeds of approximately $65.0 million, after deducting the fees and other offering expenses.

On February 23, 2021, the Company granted options to purchase an aggregate of 7,655,875 shares of the Company’s common stock to employees with an exercise price of $1.22, with a term of ten years, vesting 1/3 on the first anniversary and 1/36th each month thereafter for 24 months. Additionally, the Company granted options to purchase 4,830,000 shares of the Company’s common stock to certain employees with an exercise price of $1.53, with a term of ten years, vesting 1/3 on the first anniversary and 1/36th each month thereafter for 24 months.

On March 5, 2021, the Company announced that it entered into a $2.9 million non-binding Purchase and Sales Agreement in connection with a property in Massachusetts. The Property is intended for process development activities.